Trichostatin A (TSA)

目录号：S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA)是一种HDAC抑制剂，无细胞试验中IC50为1.8 nM左右。

规格 价格 库存 购买数量  
RMB 2022.93 现货
RMB 3660.93 现货
RMB 7125.3 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献25篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Trichostatin A (TSA)是一种HDAC抑制剂，无细胞试验中IC50为1.8 nM左右。
靶点
HDAC [1]
(Cell-free assay)
~1.8 nM
体外研究

Trichostatin A 抑制八种乳腺癌细胞系，包括MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3增殖，平均IC50为124.4 nM (范围为26.4-308.1 nM),作用于表达ERα的细胞系比作用于表达 ERα阴性的细胞系更有效。Trichostatin A作用于全部乳腺癌细胞系，抑制HDAC活性，平均IC50为 2.4 nM (范围为0.6-2.6 nM), 产生显著的组蛋白 H4高度乙酰化。[1]与 Trapoxin (TPX) 和 Chlamydocin 有效抑制HDAC1 或 HDAC4而不是 HDAC6不同，Trichostatin A 抑制这些HDACs，且抑制程度相似， IC50 分别为6 nM, 38 nM, 和8.6 nM。[2] Trichostatin A (100 ng/mL) 作用于MIA PaCa-2细胞，通过招募p300和 PCAF进入Sp1-NF-Y HDAC复合体，而诱导转化生长因子βⅡ型受体(TβRII) 表达，复合体与TβRII 启动子的DNA片段结合，伴随着Sp1乙酰化，且与复合体相关的HDAC数理全部降低。[4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 M3jOR2Z2dmO2aX;uJGF{e2G7 NHO3dGExNjgQvF2= NWPXU2dQOjSq MnTt[ZRp[W6xbB?= NX;Z[JVo\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= NGnqN40zPTd6N{C3PS=>
TE13 MY\GeY5kfGmxbjDBd5NigQ>? Ml\oNE4{|ryP M4TaNFI1cA>? Mom3eZAuemWpdXzheIV{KFKDU2PGOWEhdGW4ZXy= NI\PRXozPTV5OU[2OS=>
TE13 NGrWUZpCeG:ydH;zbZMhSXO|YYm= NULWN2U6OC5|zszN NWTEWphHOjSq MmLlbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? M4j1elI2PTd7Nk[1
MEFs M3;ER2Z2dmO2aX;uJGF{e2G7 MX[1{txO MnLmNVZp MV\pcoNz\WG|ZYOgeIhmKEWSRVOgZZR1[WOqbXXueEwhXGm{IHTlcIl3\XK7IHHu[EB1cGViZX\mbYNq\W6leTDv[kBx\WSnc4ThcEBnd3KvYYTpc44> NGHiSHozPTR6Mk[zOC=>
SW480  MYLGeY5kfGmxbjDBd5NigQ>? M3LhUVAvOc7:TR?= NGPBcVA1QGh? M321UGROW09? MVjy[ZZmenOnczDFUXQ> NHTvdYYzPTR|NEm5Oy=>
PC3  NIn5dJZHfW6ldHnvckBCe3OjeR?= MX6wMlHPxE1? NFrrNFA1QGh? MYTEUXNQ MnjpdoV3\XK|ZYOgSW1V MnHaNlU1OzR7OUe=
SW480  NX\tfGYzTnWwY4Tpc44hSXO|YYm= MV2wMlHPxE1? MV[0PIg> Ml7mSG1UVw>? NGfl[nVifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MUKyOVQ{PDl7Nx?=
PC3  NUj3cmkyTnWwY4Tpc44hSXO|YYm= NHi2eocxNjIQvF2= MWG0PIg> NYKwVW5lTE2VTx?= NYTtZW9F[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u MnnKNlU1OzR7OUe=
SW480  MVrGeY5kfGmxbjDBd5NigQ>? NVPFbGgyOC5zzszN NHvpN5E1QGh? NHHVbHhFVVOR MUfpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz NWXFbXI5OjV2M{S5PVc>
PC3  MkTzSpVv[3Srb36gRZN{[Xl? M{XDTlAvOc7:TR?= MYC0PIg> M1z3SGROW09? NYLXdYxKcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= MYiyOVQ{PDl7Nx?=
A431 NIHVeZBCeG:ydH;zbZMhSXO|YYm= NHS0eHUzNzFyL{WwM|ExOG6P M3fKe|Q5cA>? MXHEUXNQ M3j5TIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aB?= MXGyOVM4OTB4OR?=
A431 NH\nXpNHfW6ldHnvckBCe3OjeR?= NYf2WIRYPTCwTR?= NEjCOlgzNzZxMUKvNlRp NYezVZl3TE2VTx?= MUXhZ5RqfmG2ZYOgdFIyKGGwZDDpcohq[mm2czDBWGY{KGW6cILld5Nqd25? MYKyOVM4OTB4OR?=
MDA-MB-231 M3XTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUewMVYxOG6P Mkm5NlRp NXm5Z41MTE2VTx?= M3XucGlEPTBib3[gNVAxdk1? NVO3UXk6OjVzOUK3NlE>
MCF7 NYTZVIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrabYtTOC14MEDuUS=> MWOyOIg> NXi0[4xWTE2VTx?= M3jWXWlEPTBib3[gO|VvVQ>? MVqyOVE6Ojd{MR?=
SKOV-3 M3zFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7qTHF[OS1zMN88US=> NImwdmczPGh? MUnEUXNQ NVLGe2F1UUN3MDDv[kA2NjcQvF2= NV;6UJdYOjVzNkm0PVE>
A549 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPJVFdjOS1zMN88US=> M1q1cVI1cA>? NF\vN4hFVVOR NWjaTmRXUUN3MDDv[kA{NjMQvF2= M17Xd|I2OTZ7NEmx
SKOV-3 NVnZPWd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr6fI46OC5zLUJOwG0> NIfxPWU1QGh? MUPEUXNQ NFHMfY9KSzVyIH;mJFAvP87:TR?= M1XMclI2OTZ7NEmx
A549 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITyS48xNjFvMd88US=> MmDwOFhp MkjmSG1UVw>? NHew[ZhKSzVyIH;mJFAvOjkQvF2= NV6weZZwOjVzNkm0PVE>
SKOV-3 NXrT[YljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuwMlAyNTBwOd88US=> M2nxO|czcA>? NYXJUnluTE2VTx?= MUjJR|UxKG:oIECuN|LPxE1? MnvjNlUyPjl2OUG=
A549 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HNXVAvODFvMD65{txO MWC3Nog> MnLrSG1UVw>? NF\SUXpKSzVyIH;mJFAvODcQvF2= M2XO[FI2OTZ7NEmx
HeLa MXfGeY5kfGmxbjDBd5NigQ>? NVi1cZFrOjVybl2= NIOyXXQyPmh? MnzwSG1UVw>? M1q0[olv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= MmTONlUyOTZ4OEi=
CNE2 Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXiNVAxNTZyMH7N NFP2dY0zPC92OD:3Nog> M{HzV4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVfxSFdHOjR7Nkm5NFE>
PC3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXPNVAxNTFyMEDuUS=> MVqyOIg> MYnJR|UxKG:oIEOwNI5O M2TsNVI1QDV2NkW4
LNCaP NFXCTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDEUJYyODBvMUCwNI5O MnPENlRp Mo[2TWM2OCCxZjCzNFBvVQ>? MViyOFg2PDZ3OB?=
HeLa  NIniXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fjUlLPxE1? MUe0PIg> Mkn6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHic5V1KDJ3JR?= NG\Wd4MzPDh2NkGzOS=>
HMEC-1  MkjHSpVv[3Srb36gRZN{[Xl? MoPvN|Axdk1? MXWyOIg> NEDtcVVqdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZtMgWmVITlJ|wrDtVm5C MnPsNlQ4OTB4M{G=
HeLa M2f5O2Z2dmO2aX;uJGF{e2G7 NUG2eIlqOW2P NXXPOZZqOC53aB?= MYThZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl? MWOyOFcxPzR5NB?=
ACP02 M2nJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGwdVczPTBxM{WwM|UxOG6P MWOyOIg> NW\HbGti\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= M4Py[lI1PjZ6NUS3
ACP03 MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LadVI2OC9|NUCvOVAxdk1? MWeyOIg> MY\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O NYfVdpg1OjR4Nki1OFc>
U87 GBM MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXHNVAxNzNyMD:1NFAhdk1? M2rae|czKGh? NXHYeWlbOTByJTDleIhidm:u NGL1WHhz\WS3Y3XzJI1m[W5iY3XscEBvfW2kZYKgZpkhOzFuIEW0MEBidmRiNUlCpEU> Mo\JNlQ1PjR6NEG=
U87 GBM MXnGeY5kfGmxbjDBd5NigQ>? MVuxNFAwPTByIF7t M2LoWVQ5KGh? NYC0[2JjOTByJTDleIhidm:u MlfNTY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 M3iyN|I1PDZ2OESx
RPE NWHlXGpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DzdVAvOi9yLkSvNE45NzFizszN MYqyOE81QC95MjDo M2C5e2ROW09? MVHpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDifUBk\WyuIHP5Z4xmKGG{cnXzeC=> MX2yOFQ2PjZyMh?=
HT29  NGHGOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\iSFE5OCCwTR?= MoG5O|IhcA>? MVnJR|UxKG:oIEG4NEBvVQ>? MYeyOFM3QDJ4NR?=
hMSCs MXfGeY5kfGmxbjDBd5NigQ>? NETncmM3NjJ3IH7N NH[3PIIzPCCq MVHEUXNQ M1;HZpN1[WKrbHn6[ZMhUGm|dH;u[UBC[2W2eXzheIlwdiCjbnSgeIhmKEW6cILld5Nqd25ib3[gVIx2emmyb4TlcpQhT2WwZYO= M17wU|I1OzF{M{W2
Huh7  M4Hq[GZ2dmO2aX;uJGF{e2G7 NVnnV5RpOC5zL{CuOU8yNjBizszN MoG2NlRp M3SzepN2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= MmDwNlQzPjl4N{K=
SKOV3 NVixU2lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSwMlA2NTJizszN MoH6NVAwOjRxNEigbC=> NV7JWYpsTE2VTx?= MlTDcYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MXWyOFIzOzhyMR?=
A2780 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnDfVhUOC5yNT2yJO69VQ>? NY\lbohJOTBxMkSvOFghcA>? NXmxb496TE2VTx?= Mny4cYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MX2yOFIzOzhyMR?=
SRA01/04  Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPWN4xoOC5{IN88US=> Mo\NOFghcA>? M4\BSWROW09? NV3VeGFSe3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? MnTGNlQyPTd6N{i=
HLEB3 MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf2O4UxNjJizszN MljiOFghcA>? M4LLOmROW09? NIj3TVh{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? M1j1WVI1OTV5OEe4
SRA01/04  NWmxSnJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nm[FAvPC9yLkig{txO NIHq[Xg1QCCq M2D6XGROW09? NE\WbHhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVrIN|BsOjRzNUe4O|g>
HLEB3 NHGxSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jXWlAvPC9yLkig{txO MnjGOFghcA>? NIf1VodFVVOR MVXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MU[yOFE2Pzh5OB?=
HCT116 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fmNVAvOiEQvF2= NXLNXI41OTJiaB?= Mmf1[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36= Mmj3NlQyOjJ{M{G=
CA46 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HFeFMwPi9zMj:yOE81QCCwTR?= NVnXVJVbPDhiaB?= MWrpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGG2IEK0JIFv\CB2ODDuUeKh M3TQdlI1ODZ2OUWx
PMNs MYfGeY5kfGmxbjDBd5NigQ>? MmTnN|Ahdk1? NV7u[41CPDhiaB?= MlywbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 MV[yN|k5QDZzNx?=
H1299 NY\tW5g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL4fVgyyqEQvF5CpC=> MWeyOE81QC95MjDo MWHleIhidm:u MkTQbY5kemWjc3XzJINmdGxiZHXheIgh[W[2ZYKgNlRp NVTW[Jg5OjN7MU[2NFk>
A549 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TleVAvOjVxMD61M|Eh|ryP NWmwOmFEOjRxNEivO|IhcA>? NFvQUWdmfGijbn;s NIrLcJlqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MmnSNlM5Pjd7OUG=
H1299 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\RfG4xNjJ3L{CuOU8yKM7:TR?= M3T6W|I1NzR6L{eyJIg> NFGxNWdmfGijbn;s M3\oR4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NUTaVXB2OjN6Nke5PVE>
A549 Mnv4RZBweHSxc3nzJGF{e2G7 NHzFWZExNjVxMTFOwG0> NGnwfmM1QCCq MXTleIhidm:u NEnwTWZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M3XmflI{QDZ5OUmx
H1299 NFy2R3VCeG:ydH;zbZMhSXO|YYm= M2nJ[lAvPS9zIN88US=> M1\1eVQ5KGh? NH:4Oo5mfGijbn;s M{P1b4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NV\ncG9NOjN6Nke5PVE>
SUM149PT MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli2Nk84NjVxMUCg{txO NH\QOnI1QCCq MYXEUXNQ NHn1fVZqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= NFLoVGszOzd7Mk[zPC=>
SUM190PT MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DOTVUxNzFyMD:yOVAhdk1? NH3Id2E1QCCq NFH5eVJFVVOR M3HHU4lv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? NWWzW2RUOjN5OUK2N|g>
HCT1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[zeokxNjJxMT6wM|UvOCEQvF2= Mmj0NVIwOjRxM{[vOFghcA>? NF3oTJVqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MXeyN|c4ODByMB?=
Lovo MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnDWo1HOC5{L{GuNE82NjBizszN MUKxNk8zPC9|Nj:0PEBp MXrpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MoS4NlM4PzByMEC=
AGS NULQWJdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHIc4F2OC5yMUWtNUDPxE1? NEj0[404OiCq NXn2cGh6cW6mdXPld{Bk\WyuIHTlZZRpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NHP0cWIzOzd2NUCyOC=>
Huh7 NYnkeo5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[xJO69VQ>? MWqyOEBp M{PxVmROW09? NIrabYVz\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>? NX7QVFhqOjN4NEO5N|M>
ECC1 NWPCRWpNTnWwY4Tpc44hSXO|YYm= M4nNWFUxOCCwTR?= M4jrclUh\A>? MnPGSG1UVw>? NF;VcWZqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NUXUOHAxOjN3M{C3Olk>
HEC1A NWXMeI1GTnWwY4Tpc44hSXO|YYm= M{LnWlUxOCCwTR?= MUG1JIQ> NHnlNFBFVVOR M4TsV4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF M2i3blI{PTNyN{[5
EN1 Mn[5SpVv[3Srb36gRZN{[Xl? MkHJOVAxKG6P MV21JIQ> NIjiV|hFVVOR NFThcnVqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MlXYNlM2OzB5Nkm=
MFE296 MX3GeY5kfGmxbjDBd5NigQ>? MVq1NFAhdk1? MWm1JIQ> M3\S[WROW09? NXPOcFRFcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NUPZRWViOjN3M{C3Olk>
HASMCs NGXQeFdHfW6ldHnvckBCe3OjeR?= MoThNE02ODBibl2= MUK2JIQ> MkLN[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk> MkTzNlM2OTh2Nke=
U373 MWPGeY5kfGmxbjDBd5NigQ>? Mnq4NE4zPS9yLkWvNUDPxE1? MVyyOEBp NG\xVGdqdmO{ZXHz[ZMhWFJvQjDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFVCgmGmQx?= MVOyN|Q4PDF5MR?=
ARN8  NIrUbYNHfW6ldHnvckBCe3OjeR?= NEK0PHIxNjB3LUKg{txO MV6yOEBp MUfy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> M4q1fFI{PDdyNUSw
MCF7 NGPTb45HfW6ldHnvckBCe3OjeR?= NV25eZZCOC5yNT2yJO69VQ>? NX;MWZJ4OjRiaB?= MV;y[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> NGfqO2MzOzR5MEW0NC=>
H1299  NWfjcGRtTnWwY4Tpc44hSXO|YYm= M1nHZlAvOzQkgKOxxsDDvU1? M{LF[|I1NzR6IHi= M4n1ZmROW09? NHTqWIJqdmO{ZXHz[ZMhTS2lYXTo[ZJqdiCycn;0[YlvKGyndnXsd{Bld3OnIHTldIVv\GWwdHz5 MXuyN|Q3OTl5NR?=
H1299 M1z4OGZ2dmO2aX;uJGF{e2G7 NEfkT2UxNjVizszN MUi0PEBp M3PyeGROW09? NUDsTVFwcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MWGyN|Q3OTl5NR?=
H1299 M{K0cmZ2dmO2aX;uJGF{e2G7 M36wfVAvPSEQvF2= M2fYV|Q5KGh? MXrEUXNQ MnqybY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW|c9MgJINwdWKrbnWge4l1cCC|aXzpZolvcW5? NWjNfYRFOjN2NkG5O|U>
MG-63  MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfJbVhKOC5|IN88US=> MnO5NVIuQTZiaB?= MVHEUXNQ NHLFO5lqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu NFvZOYMzOzR3MUixOy=>
LM8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFriNYcxNjNizszN MV[xNk06PiCq NIi0d5JFVVOR M16zTIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= M1H1fFI{PDVzOEG3
K562 NV7rfpJHTnWwY4Tpc44hSXO|YYm= M2f4[lAvPSEQvF2= M2myeVI1KGh? M{\x[IV1cGGwb3y= MYLk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> M3LYeVI{PDNyOUW3
HEL NFnuUI1HfW6ldHnvckBCe3OjeR?= NWDvPIczOC53IN88US=> NIrDO5IzPCCq MXHleIhidm:u M3Sw[YRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv M3\0RVI{PDNyOUW3
HL60 MUXBdI9xfG:|aYOgRZN{[Xl? MlTmNUDPxE1? NYHrSWtoOjRiaB?= NEXFUZFqdmS3Y3XzxsBk\WyuIHTlZZRp M2K1TFI{PDByNUG5
KG1 MnTQRZBweHSxc3nzJGF{e2G7 NXHHXHBFOSEQvF2= M3nERVI1KGh? MWXpcoR2[2W|wrDj[YxtKGSnYYTo NG\CNVIzOzRyMEWxPS=>
Kazumi M3OzW2Fxd3C2b4Ppd{BCe3OjeR?= NYHVNHZSOSEQvF2= MmHHNlQhcA>? NVHOdXNzcW6mdXPld:Kh[2WubDDk[YF1cA>? MnXxNlM1ODB3MUm=
K562 MV\BdI9xfG:|aYOgRZN{[Xl? NYDDV|B7OSEQvF2= NVHGXWRYOjRiaB?= NIryepRqdmS3Y3XzxsBk\WyuIHTlZZRp MW[yN|QxODVzOR?=
THP1 NY\6[mxSSXCxcITvd4l{KEG|c3H5 NYC2SGtPOSEQvF2= MonPNlQhcA>? MXnpcoR2[2W|wrDj[YxtKGSnYYTo NUDHdnNNOjN2MEC1NVk>
SH-SY5Y MXrGeY5kfGmxbjDBd5NigQ>? NEW1UZUzPTBibl2= MlnNNVYhcA>? M2PROoNp[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= M3\SSlI{OzJ4NEKy
HEK293 NUnvSYEzTnWwY4Tpc44hSXO|YYm= NYrC[HVHOSEEtV5CpC=> NHy3UpEyQCCqwrC= NVPqRmQzcW6qaXLpeJMhfGinIHvhcIlzcW5vNz3t[YRq[XSnZDDy[YNzfWm2bXXueEBw\iC|eX7wbIltcW5vMTDh[4dz\WejdHXzJIlvfG9iYXfndoV{d22ncx?= MVOyN|I5PDh2OB?=
HTK MmLESpVv[3Srb36gRZN{[Xl? NWPWN3o1PDByIH7N NFiwVno4OiCq MkLSbY5pcWKrdIOgWGdHNc7{4pETTY5lfWOnZDDNfY9ncWK{b3LsZZN1KESrZn\ldoVvfGmjdHnvci=> MkK3NlMzQDRyMEK=
HTK M4TMfWZ2dmO2aX;uJGF{e2G7 MoPXNVAxNThyMH7N NYXEV|RtPzJiaB?= MkDwZoxw[2u|IGTHSk3PuuLCk1nu[JVk\WRiUl;TJIFv\CCKMl:yxsBC[2O3bYXsZZRqd25? M1HZTVI{Ojh2MECy
Caco-2  M4LRVWZ2dmO2aX;uJGF{e2G7 MnjiNUDDvU4EoB?= M{GwV|I1KGh? M1uxbIRm[3KnYYPld{BUTVKWIIDyc5RmcW5iZYjwdoV{e2mxbh?= M4nNVVI{OTl3MEew
HeLa NVzSW2liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYOxNFAhdk1? MVGyOEBp MXfEUXNQ NWjnfY96UUN3MDDv[kAyODCwTR?= M1XxVVI{OTZ3N{S4
HeLa M{\0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTKOFAhdk1? M1rIflQ5KGh? NYG1c4hMTE2VTx?= NX2xS3hUUUN3MDDv[kA1OG6P MXGyN|E3PTd2OB?=
HeLa MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXGNlAhdk1? NUTBdVNvPzJiaB?= Mmq0SG1UVw>? NYHmSXVlUUN3MDDv[kAzOG6P M4jNWVI{OTZ3N{S4
HeLa MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TzflExNzNyL{WwJI5O MmDnO|IhcA>? NFTNOZJFVVOR NUKwboU1cW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 MW[yN|E3PTd2OB?=
MDA-MB-231 M3;qcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nVe|I2NTRyMDDuUS=> MXS0PEBp MVjJR|UxKG:oIEK2N{4zdk4EoB?= MYOyN|A2PTF7OB?=
MCF-7  MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUiyOU01ODBibl2= M3zrXVQ5KGh? MULJR|UxKG:oIEKyNE41dk1? Mn3HNlMxPTVzOUi=
ECC-1  NXfkWXBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxNFAhdk1? NYjKe3RoOjRiaB?= NEHTdppmfGijbn;s M1K3T4lv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= MkjNNlMxOjh6MEO=
HEC-1A M3HDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLCO|RSOTByIH7N NV7WSlBvOjRiaB?= NEL1XIhmfGijbn;s NX\ubm8ycW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{ml NGLNNY0zOzB{OEiwNy=>
NHAC-kn NHHFdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvhNVAwOTByL{WwNEBvVQ>? MonENVIhcA>? NEi4b|dFVVOR MYfJR|UxKG:oIEWwNI5O NHrGVoczOzBzN{i3NS=>
A549 M2PsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fGUVI2OCCwTR?= M{izRVYuPzJiaB?= M364d2ROW09? NXPQfnpN[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? NGH3RXMzOjl7NEe4NC=>
MG-63 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\V[GxVOzByIH7N NETUcYsyOiCq MmC1SG1UVw>? MkHMbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFg3LQ>? MVqyNlc6QTN|OB?=
MG-63 Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWezNFAhdk1? MXGyOEBp MXrEUXNQ MWfpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOlcm NY\QephoOjJ5OUmzN|g>
MG-63 M4C5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGzNFAhdk1? MY[0PEBp NF7r[I9FVVOR NITPZlZqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn MWGyNlc6QTN|OB?=
HL60  MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWxOVAuOzVyIH7N NG\LVZEzPCCq NXj2XoFicW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? NXPIepp[OjJ5NUO3N|k>
U937 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vuflE2OC1|NUCgcm0> MVOyOEBp MX;pcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N MlXSNlI4PTN5M{m=
SCC-6 M3;BSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TNclIxOC1|MkCwJI5O NUD3fHhOOTJxMkSvOFghcA>? MmjwSG1UVw>? MYLpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NH\PWIczOjV3MkOyNS=>
U87  MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LBcVExOC1|MECgcoc> MoLrNlQhcA>? Mki5bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFczLSBiYYSgNlAxdmd? NYfGT5VYOjJ{N{C4OFk>
K562 NUjCNo5lTnWwY4Tpc44hSXO|YYm= MYCxJO69VQ>? NUTQ[2Z2OTJiaB?= MnPzSG1UVw>? M3rVWYVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS NE\EWIUzOjF5OUG5PC=>
Reh M2\kZWZ2dmO2aX;uJGF{e2G7 MoXnNE4{NzFizszN MWCxNkBp Mmr3SG1UVw>? NXrQbmZH\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> NHP0N|AzOjF5OUG5PC=>

... Click to View More Cell Line Experimental Data
体内研究 Administration of Trichostatin A 按 0.5 mg/kg 剂量处理N-甲基-N-亚硝基脲致癌物诱发的大鼠乳腺癌模型，持续处理4周，具有有效的抗癌活性，即使按按高达5 mg/kg剂量处理也没有任何可测量到的毒性。[1]Trichostatin A 按10 mg/kg 剂量单独腹腔注射给药非转基因和脊髓性肌萎缩症（SMA）模型鼠，导致乙酰化的 H3 和 H4组蛋白水平提高，也导致活运动神经元(SMN) 基因表达稍微提高。Trichostatin A 每天按10 mg/kg剂量处理SMA模型鼠，促进存活, 减轻体重下降,且增强运动行为。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[1]
+ 展开

体外HDAC活性 :

从每种乳腺癌细胞系(MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51,或 SK-BR-3)中准备全部细胞提取物。在溶于0.1% (v/v)乙醇的不同浓度Trichostatin A存在时，或者使用0.1% (v/v)乙醇作为对照, 20 μL 细胞粗提取物(~2.5 ×105 个细胞)与 1 μL ~1.5 × 106 cpm [3H]乙酰标记的组蛋白 H4 肽底物(第2-20位NH2-末端残基) 在25oC下温育60分钟。使用50 μL 1 M HCl/0.16 M 乙酸对每组 200-μL 反应进行淬火，然后使用600 μL 乙酸乙酯进行抽提，通过闪烁计数器测量释放的[3H]乙酸。使用非线性回归曲线拟合抑制数据，绘制合适的剂量反应曲线，而测定IC50。
细胞实验：[1]
+ 展开
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, 和 SK-BR-3
  • Concentrations: 溶于无水酒精,终浓度为~10 μM
  • Incubation Time: 96小时
  • Method: 使用不同浓度Trichostatin A处理细胞96小时。处理后,使用sulforhodamine B 比色分析测定细胞增殖。通过台酚蓝染色排除法测定细胞活力。
    (Only for Reference)
动物实验：[1]
+ 展开
  • Animal Models: 携带NMU诱导的肿瘤的近交系(Ludwig/Wistar/Olac)处女鼠
  • Formulation: 溶于DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: 皮下注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
2% DMSO+30% PEG 300+2% Tween 80+ddH2O 		3mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 302.4
化学式

C17H22N2O3
CAS号 58880-19-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答：

    Our S1045 Trichostatin A (TSA) is R enantiomer.

Selleck产品目录册

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

  • LMK-235 New

    LMK-235是HDAC4和HDAC5的选择性抑制剂， IC50分别为11.9 nM 和 4.2 nM。

  • CAY10603 New

    CAY10603是一种强效的选择性HDAC6抑制剂，IC50为2 pM，选择性比其它HDACs高200多倍。

  • Domatinostat (4SC-202) New

    4SC-202是一种选择性的I类HDAC抑制剂，对HDAC1，HDAC2，和HDAC3的IC50分别为1.20 μM，1.12 μM，和0.57 μM。也对Lysine specific demethylase 1 (LSD1)表现出抑制活性。Phase 1。

  • Panobinostat (LBH589)

    Panobinostat (LBH589)是一种新型的，广谱HDAC抑制剂，无细胞试验中IC50为5 nM。Phase 3。

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA)是一种HDAC抑制剂，无细胞试验中IC50为~10 nM。

    Features:Vorinostat是广谱HDAC活性抑制剂，抑制I和II类酶 。

  • Entinostat (MS-275)

    Entinostat (MS-275)强烈抑制HDAC1和HDAC3，无细胞试验中IC50分别为0.51 μM和1.7 μM，抑制作用强于HDACs 4， 6， 8，和10。Phase 3。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1和HDAC2抑制剂，无细胞试验中IC50分别为36 nM和47 nM。

    Features:Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。

  • RGFP966

    RGFP966是一种HDAC3抑制剂，无细胞试验中IC50为0.08μM ，比作用于其他HDAC选择性高200倍以上。

  • Tubastatin A

    Tubastatin A是一种有效的，选择性HDAC6抑制剂，无细胞试验中IC50为15 nM，选择性远高于所有其他同工酶(1000倍)除了HDAC8(57倍)。

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103)是一种有效的HDAC抑制剂，对HDAC1抑制作用最强，无细胞试验中IC50为0.15 μM，比作用于HDAC2， 3，和11选择性高2到10倍，对HDAC4， 5， 6， 7，和8没有抑制活性。Phase 2。

Tags: 购买Trichostatin A (TSA) | Trichostatin A (TSA)供应商 | 采购Trichostatin A (TSA) | Trichostatin A (TSA)价格 | Trichostatin A (TSA)生产 | 订购Trichostatin A (TSA) | Trichostatin A (TSA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID